Építés alatt – nem éles oldal
Belépés
Csak meghívásosFázis nélkül

Natural History Study of SCID Disorders

A legfontosabb adatok

Ki végzi
National Institute of Allergy and Infectious Diseases (NIAID)
Hol
Ann Arbor, Atlanta, Bethesda, Birmingham, Boston, Chicago, Cincinnati, Cleveland, Columbus, Dallas, Denver, Durham, Hackensack, Houston, Los Angeles, Madison, Memphis, Milwaukee, Minneapolis, New Orleans, New York, Palo Alto, Philadelphia, Phoenix, Pittsburgh, Portland, Rochester, Salt Lake City, San Antonio, San Francisco, Seattle, St Louis, St. Petersburg, Valhalla, Washington D.C. és Wilmington (Egyesült Államok)Mind a 39 helyszín megnézéseMég 1 másik országban, 5 helyszínen
Azonosító
Állapot
Csak meghívásos
Résztvevők
690 fő, tervezett
Kezdés
2010. szept. 2.
Várható befejezés
2028. szept.
A vizsgálat típusa
Megfigyeléses, 3 csoport
A regiszteradat frissítve
2020. november 10.

Ki vehet részt

Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 35 feltétel megnézéseKevesebb

Ki vehet részt

  • Stratum A: Typical SCID (formerly referred to as Classic SCID)- -Subjects who meet the following inclusion criteria and the intention is to treat with allogeneic hematopoietic cell transplant (HCT) are eligible for enrollment into Stratum A (Typical SCID) of the study:
  • Absence or very low number of T cells (CD3 T cells <300/microliter) AND
  • No or very low T cell function (<10% of lower limit of normal) as measured by response to phytohemagglutinin (PHA) OR
  • T cells of maternal origin present; Stratum B: Leaky SCID, Omenn Syndrome, Reticular Dysgenesis-; -Subjects who meet the following criteria and the intention is to treat with HCT are eligible for enrollment into Stratum B:; Leaky SCID:
  • Maternal lymphocytes tested for and not detected AND
  • Either one or both of the following (a,b) :; a.) <50% of lower limit of normal T cell function as measured by response to PHA, OR response to anti-CD3/CD28 antibody; b.) Absent or <30% of lower limit of normal proliferative responses to candida and tetanus toxoid antigens
  • AND at least two of the following (a through e):; a.) Reduced number of CD3 T cells; age ≤2 years: <1500/microliter; age >2 years and ≤4 years: <800/microliter; age >4 years: <600/microliter; b.) ≥80% of CD3+ or CD4+ T cells that are CD45RO+; AND/OR >80% of CD3+ or CD4+ T cells are CD62L negative; AND/OR >50% of CD3+ or CD4+T cells express HLA-DR (at <4 years of age); AND/OR are oligoclonal T cells; c.) Hypomorphic mutation in IL2RG in a male, or homozygous hypomorphic mutation or compound heterozygosity with ≥1 hypomorphic mutation in an autosomal SCID-causing gene; d.) Low T Cell Receptor Excision Circles (TRECs) and/or the percentage of CD4+/45RA+/CD31+ or CD4+/45RA+/CD62L+ cells is below the lower limit of normal; e.) Functional testing in vitro supporting impaired, but not absent, activity of the mutant protein, AND
  • Does not meet criteria for Omenn Syndrome; Omenn Syndrome:
  • Generalized skin rash
  • Maternal lymphocytes tested for and not detected; --Note: If maternal engraftment was not assessed and ruled out, the subject is not eligible as Omenn Syndrome
  • ≥80% of CD3+ or CD4+ T cells are CD45RO+ AND/OR; 80% of CD3+ or CD4+T cells are CD62L negative AND/OR; 50% of CD3+ or CD4+ T cells express HLA-DR (at <2 years of age)
  • Absent or low (< 30% lower limit of normal) T cell proliferation response to antigens (Candida, tetanus) to which the subject has been exposed; NOTE: If proliferation to antigen was not performed, but at least 4 of the following 9 supportive criteria, at least one of which must be among those marked with an asterisk (*) below are present, the subject is eligible as Omenn Syndrome:
  • Hepatomegaly
  • Splenomegaly
  • Lymphadenopathy
  • Elevated IgE
  • Elevated absolute eosinophil count
  • *Oligoclonal T cells measured by CDR3 length or flow cytometry
  • *Proliferation to PHA is reduced <50% of lower limit of normal or SI <30
  • *Hypomorphic mutation in a SCID causing gene
  • Low TRECS and/or the percentage of CD4+/45RA+/CD31+ or CD4+/45RA+/CD62L+ cells is below the lower limit of normal; Reticular Dysgenesis:
  • Absence or very low number of T cells (CD3 <300/µL
  • No or very low (<10% lower limit of normal) T cell response to PHA
  • Severe neutropenia (absolute neutrophil count < 200 /µL) AND
  • ≥2 of the following (a,b,c):; a.) Sensori-neural deafness; b.) Deficiency of marrow granulopoiesis on bone marrow examination; c.) A pathogenic mutation in the adenylate kinase 2 (AK2) gene identified; Stratum C:; Subjects who meet the following criteria and the intention is to treat with therapy other than allogeneic HCT, primarily PEG-ADA ERT or gene therapy with autologous modified (gene transduced) cells, are eligible for enrollment into; Stratum C:
  • ADA Deficient SCID with intention to treat with PEG-ADA ERT
  • ADA Deficient SCID with intention to treat with gene therapy
  • X-linked SCID with intention to treat with gene therapy
  • Any SCID patient previously treated with a thymus transplant (includes intention to treat with HCT, as well as PEG-ADA ERT or gene therapy)
  • Any SCID patient who received therapy for SCID deemed "non-standard" or "investigational", including in utero procedures

Ki nem vehet részt

  • Presence of an Human Immunodeficiency Virus (HIV) infection (by PCR) or other cause of secondary immunodeficiency
  • Presence of DiGeorge syndrome
  • Metabolic conditions that imitate SCID or related disorders such as folate transporter deficiency, severe zinc deficiency or transcobalamin deficiency
  • -Subjects who meet any of the following exclusion criteria are disqualified from enrollment in Strata A, B, or C of the study:
  • MHC Class I and MHC Class II antigen deficiency, and

Helyszínek itt: Egyesült Államok

Még 1 másik országban, 5 helyszínen

  • University of Michigan Health SystemAnn Arbor, Egyesült ÁllamokCsak meghívásos
  • Children's Healthcare of Atlanta/Emory University School of MedicineAtlanta, Egyesült ÁllamokCsak meghívásos
  • NIH Clinical Center Genetic Immunotherapy SectionBethesda, Egyesült ÁllamokCsak meghívásos
  • University of Alabama at BirminghamBirmingham, Egyesült ÁllamokCsak meghívásos
  • Children's Hospital, BostonBoston, Egyesült ÁllamokCsak meghívásos
  • Ann & Robert H. Lurie Children's Hospital of ChicagoChicago, Egyesült ÁllamokCsak meghívásos
  • Cincinnati Children's Hospital Medical CenterCincinnati, Egyesült ÁllamokCsak meghívásos
  • University Hospitals Rainbow Babies and Children's HospitalCleveland, Egyesült ÁllamokCsak meghívásos
  • Nationwide Children's HospitalColumbus, Egyesült ÁllamokCsak meghívásos
  • University of Texas Southwestern Medical Center/Children's of DallasDallas, Egyesült ÁllamokCsak meghívásos
  • Children's Hospital DenverDenver, Egyesült ÁllamokCsak meghívásos
  • Duke UniversityDurham, Egyesült ÁllamokCsak meghívásos
  • Hackensack University Medical CenterHackensack, Egyesült ÁllamokCsak meghívásos
  • Texas Children's HospitalHouston, Egyesült ÁllamokCsak meghívásos
  • Children's Hospital Los AngelesLos Angeles, Egyesült ÁllamokCsak meghívásos
  • University of California, Los AngelesLos Angeles, Egyesült ÁllamokCsak meghívásos
  • University of Wisconsin-American Family Children's HospitalMadison, Egyesült ÁllamokCsak meghívásos
  • St. Jude Children's Research HospitalMemphis, Egyesült ÁllamokCsak meghívásos
  • Medical College of WisconsinMilwaukee, Egyesült ÁllamokCsak meghívásos
  • University of Minnesota Medical CenterMinneapolis, Egyesült ÁllamokCsak meghívásos
  • Children's Hospital/Louisiana State University Health Sciences CenterNew Orleans, Egyesült ÁllamokCsak meghívásos
  • Memorial Sloan-Kettering Cancer CenterNew York, Egyesült ÁllamokCsak meghívásos
  • Lucile Salter Packard Children's Hospital at StanfordPalo Alto, Egyesült ÁllamokCsak meghívásos
  • The Children's Hospital Of PhiladelphiaPhiladelphia, Egyesült ÁllamokCsak meghívásos
  • Phoenix Children s HospitalPhoenix, Egyesült ÁllamokCsak meghívásos
  • Children's Hospital of Pittsburgh of UPMCPittsburgh, Egyesült ÁllamokCsak meghívásos
  • Oregon Health and Science UniversityPortland, Egyesült ÁllamokCsak meghívásos
  • Mayo Clinic HospitalRochester, Egyesült ÁllamokCsak meghívásos
  • University of Rochester Medical Center/ Golisano Children's HospitalRochester, Egyesült ÁllamokCsak meghívásos
  • Primary Children's Medical Center/University of UtahSalt Lake City, Egyesült ÁllamokCsak meghívásos
  • Methodist Children's Hospital of South Texas/Texas Transplant InstituteSan Antonio, Egyesült ÁllamokCsak meghívásos
  • University of California San Francisco Children's HospitalSan Francisco, Egyesült ÁllamokCsak meghívásos
  • Seattle Children's Research InstituteSeattle, Egyesült ÁllamokCsak meghívásos
  • Cardinal Glennon Children's Medical CenterSt Louis, Egyesült ÁllamokCsak meghívásos
  • Washington University/St. Louis Children's HospitalSt Louis, Egyesült ÁllamokCsak meghívásos
  • Johns Hopkins All Children's HospitalSt. Petersburg, Egyesült ÁllamokCsak meghívásos
  • New York Medical College, Maria Fareri Children's HospitalValhalla, Egyesült ÁllamokCsak meghívásos
  • Children's National Medical CenterWashington D.C., Egyesült ÁllamokCsak meghívásos
  • Alfred I. duPont Hospital for Children/NemoursWilmington, Egyesült ÁllamokCsak meghívásos

A vizsgálatról

Mit akar kideríteni a vizsgálat

This study is a prospective evaluation of children with Severe Combined Immune Deficiency (SCID) who are treated under a variety of protocols used by participating institutions. In order to determine the patient, recipient and transplant-related variables that are most important in determining outcome, study investigators will uniformly collect pre-, post- and peri-transplant (or other treatment) information on all children enrolled into this study.

A teljes eredeti leírásKevesebb

Children will be divided into three strata:

* Stratum A: Typical SCID with virtual absence of autologous T cells and poor T cell function * Stratum B: Atypical SCID (leaky SCID, Omenn syndrome and reticular dysgenesis with limited T cell diversity or number and reduced function), and * Stratum C: ADA deficient SCID and XSCID patients receiving alternative therapy including PEG-ADA ERT or gene therapy.

Each Group/Cohort Stratum will be analyzed separately.

A vizsgálat 3 csoportja

  • Stratum A: Typical SCID +HCT

    Stratum A: Typical Severe Combined Immunodeficiency (SCID) treated with HCT therapy. Participants with typical (formerly referred to as classic) SCID + allogeneic hematopoietic stem cell transplantation (HCT) therapy according to standard of care, per local protocol.

  • Stratum B: Atypical SCID +HCT

    Stratum B: Atypical Severe Combined Immunodeficiency (SCID) treated with HCT therapy. Participants with leaky SCID, Omenn syndrome, or Reticular Dysgenesis (RS) + allogeneic hematopoietic stem cell transplantation (HCT) therapy according to standard of care, per local protocol.

  • Stratum C:SCID +Non-HCT

    Stratum C: Severe Combined Immunodeficiency (SCID) who receive alternative therapy per standard of care, non-standard care and/or investigational. This stratum includes: * Adenosine Deaminase-Deficient SCID (ADA Deficient SCID) with intention to treat with Polyethylene Glycol -Adenosine Deaminase Enzyme Replacement Therapy (PEG-ADA ERT) * ADA Deficient SCID with intention to treat with gene therapy * X-linked SCID (XSCID) with intention to treat with gene therapy * Any individual with SCID previously treated with a thymus transplant (includes intention to treat with HCT, as well as PEG-ADA ERT or gene therapy)

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children With SCID Disorders (RDCRN PIDTC-6901)
Publikációk
A regiszteradat frissítve
2020. november 10.